We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fallout Over Zolgensma Data Manipulation Spreads
Novartis is facing fresh scrutiny after a Swiss newspaper revealed on Sunday that an unnamed executive at the drugmaker sold nearly $1 million in company stock just weeks before news broke of the data manipulation surrounding Zolgensma, its $2 million spinal muscular atrophy treatment.